


Report of the 3rd Veritas Science Seminar

On May 22-23rd 2012, the 3rd Veritas Science Seminar regarding “Outline of FDA Guidance and Practical Applications” took place.

FDA released a draft of DDI Guidance in March 2012.

Researchers that were either interested in the draft FDA guidelines or in handling the Hepatocytes from Celsis IVT, gathered for the seminar.



Celsis IVT / Scientific Advisor / Tim Moeller



Celsis IVT / Consultant / Dr. Jasminder Sahi



University of Tokyo Pharmaceutical sciences /
Professor / Mr. Kazuya Maeda

Participants also had an opportunity to work with Celsis' Human Plateable Hepatocytes during a hands-on-training session.

The following are the comments from the participants:

- Easy preparation compared to other manufacturers' product.
- Surprisingly the viability rate is higher than ordinary products without using the Percoll method.
- I was able to grasp the technique without a reduction in the viability rate.
- No centrifuge in the protocol lead to a stress-free environment for the cells.

Participants' great interest was also visible at the Q&A session held in the latter half of the seminar. Moreover, the 2nd day's Q&A session extended to 4 hours, with very active discussions. The participants were enthusiastic about discussing their questions and experiences with other researchers from different institutes.

With the experience from this seminar and the feedback from a participant survey to guide us, we plan to host other hands-on training sessions and seminars for other products and applications.

Please contact us using the contact information below for a copy of the seminar materials or if you have further questions regarding the seminar or Celsis Plateable Hepatocytes.

Yuya Yokozawa
Technical Marketing and Sales Division Manager
Veritas Corporation.
Tel : 03-3593-3385
Email : techservice@veritastk.co.jp

Product information

<http://www.veritastk.co.jp/cat/MED-IVT/>